Key points are not available for this paper at this time.
A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC.
Gofrit et al. (Tue,) studied this question.